ARDELYX Q3 2026 EARNINGS - ARDELYX INC

Financial Performance:

• Total product revenue for Q3 2026 reached $125.5 million, a 19% year-over-year increase driven by strong demand for Absrela and Exposa.
• Absrela generated $96.3 million in revenue (23% YoY growth), while Exposa generated $29.2 million (7% YoY growth).
• Net loss narrowed significantly to $0.7 million in Q3 2026, compared to a $1.0 million loss in Q3 2025.
• Operating expenses rose to $119.1 million ($25.2M R&D + $93.9M SG&A), reflecting investments in the Excel Phase 3 trial and expanded sales/reimbursement teams.
• Gross profit margin remains above 95%; blended gross-to-net discount rate was 31.7% in Q3, up slightly from 30.6% in the prior year period.
• Cash, cash equivalents, and short-term investments totaled $285.3 million at quarter-end, providing robust liquidity to fund operations and pipeline development.

Guidance and Future Outlook:

• Management reaffirmed full-year 2026 revenue guidance: Absrela at $350–$370 million and Exposa at $110–$120 million.
• Full-year 2026 operating expenses are expected to remain below $500 million.
• The company maintains a target to achieve profitability in 2027.
• Long-term goal for Absrela is to achieve $1 billion in annual revenue.
• Excel Phase 3 trial results for Chronic Idiopathic Constipation (CIC) are anticipated in the second half of 2027.
• Management expects gradual improvement in payer friction over time rather than immediate dramatic inflection.

Business Segments and Product Lines:

• Absrela (IBSC): Demand reached all-time highs with growing total prescribers, prescriptions, and market share; DTC campaign launched in September targeting 10 million viewers, with 91% of tested patients indicating intent to ask physicians.
• Exposa (CKD/Hyperphosphatemia): Sales volume increased 22% in paid prescriptions despite a 9% sequential revenue decline attributed to customer buying patterns and inventory dynamics.
• Pipeline (Tanapinor/Absrela for CIC): Fully enrolled the Excel Phase 3 trial ahead of schedule for Chronic Idiopathic Constipation (CIC), leveraging overlapping symptoms with IBSC.
• Commercial Initiatives: Expanded sales force to increase HCP reach; doubled the Field Reimbursement Management (FRM) team to navigate prior authorizations; transitioning patients to the Absrela Pharmacy Network (IPN) to improve fulfillment rates and adherence.

Market and Competitive Landscape:

• IBSC market includes over 7 million annual prescriptions, with >70% of patients experiencing persistent symptoms despite current treatments.
• Exposa addresses a market of 550,000+ dialysis patients in the US, with nearly 70% struggling to maintain target phosphorus levels.
• Real-world data indicates Absrela users experience reduced GI-related healthcare resource utilization (fewer doctor visits and labs).
• CIC is a larger market than IBSC, with significant unmet need among patients who fail over-the-counter treatments.
• Competition involves payer friction and complex reimbursement environments, particularly for new biologic therapies.

Risks and Challenges:

• Payer friction and prior authorization delays remain a primary barrier to patient access and utilization.
• Exposa revenue growth was temporarily offset by dialysis customer buying patterns and inventory fluctuations.
• Regulatory and market uncertainty surrounding future contracting strategies for 2027.
• Potential data inaccuracies or reporting discrepancies in script counts as the company transitions to the IPN.
• Ongoing R&D costs associated with the Excel Phase 3 trial and potential future pediatric programs.

Management Commentary and Tone:

• Management expressed high confidence in the company's financial position, product portfolio, and execution capabilities.
• Tone was optimistic regarding Absrela's growth trajectory and the strategic value of the pipeline expansion into CIC.
• CFO emphasized the efficiency of the business model, highlighting the leverage provided by high gross margins and disciplined expense management.
• CEO reiterated the focus on "staying focused on execution and improving patient access" to drive adoption.

Analyst Questions and Answers:

• IPN Penetration: Management declined to provide specific penetration percentages, noting it is a strategic priority but premature to disclose metrics to avoid disruption.
• Exposa Long-Term Guidance: Reaffirmed a cautious approach to re-establishing long-term frameworks for Exposa until the TDAPA (terminal date for payment agreements) period concludes.
• Payer Friction Drivers: Confirmed progress in Q3 was due to improved execution (FRMs, digital tools, payer negotiations) rather than changes in underlying payer requirements.
• DTC Impact: Early metrics show increased website traffic and high patient intent, though direct translation to script growth is still being monitored.
• CIC Market Potential: Management anticipates Absrela will capture the underserved portion of the CIC market after patients fail OTC therapies, noting it will not replace first-line treatment immediately.
• Gross-to-Net: Blended rate was 31.7% in Q3; management expects this low-to-mid 30s range to persist with normal mix shifts and inflation penalties.
• Inventory/Scripting: Addressed sequential script fluctuations as likely due to channel inventory timing and data projection methods rather than fundamental demand weakness.

Other Key Points:

• The Excel Phase 3 trial enrollment for CIC was completed ahead of schedule, signaling strong physician enthusiasm.
• Real-world data presented at the American College of Gastroenterology meeting supports the health economic benefits of Absrela.
• No specific updates were provided regarding the pediatric program for Absrela.
• Management reiterated that achieving access improvements requires a multi-faceted approach including digital tools, FRMs, and thoughtful contracting, rather than a single solution.